Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.41 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29935002 | 1.00 | PLAU (0.47) | PLAUPRKCINOTUMPIK3CAFDPS | |
| SCHEMBL30504670 | 0.86 | PRKCI (0.53) | PRKCINOTUMPIK3CAEGFRCSNK1D | |
| SCHEMBL19996096 | 0.86 | PRKCI (0.53) | PRKCINOTUMPIK3CAEGFRCSNK1D | |
| SCHEMBL211823 | 0.81 | CSNK1D (0.40) | PLAUPRKCICSNK1DCSNK1EBUB1 | |
| SCHEMBL14291396 | 0.81 | SREBF2 (0.47) | PRKCINOTUMFDPSCSNK1DCSNK1E | |
| SCHEMBL13239038 | 0.81 | CSNK1D (0.59) | PRKCICSNK1DCSNK1ESREBF2S1PR1 | |
| SCHEMBL8257156 | 0.80 | SREBF2 (0.48) | PLAUNOTUMPIK3CAFDPSSREBF2 | |
| SCHEMBL2111804 | 0.80 | PLAU (0.47) | PLAUNOTUMPIK3CAFDPSEGFR | |
| SCHEMBL7387315 | 0.80 | PLAU (0.43) | PLAUNOTUMPIK3CAFDPSEGFR | |
| SCHEMBL19996104 | 0.79 | KDM4E (0.45) | PIK3CACSNK1DCSNK1ECOMTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| WO-2023069700-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069700-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-9505739-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505739-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505739-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150038490-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038490-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038490-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8865701-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| CN-1085217-A | 1,4-benzodioxan derivative | MERCK PATENT GMBH (DE) | 1994-04-13 | — | — | CN | disclosed |
| EP-0586866-A2 | 1,4,-Benzodioxane derivatives with pharmacologic properties | MERCK PATENT GmbH (DE) | 1994-03-16 | — | — | EP | disclosed |
| US-5114945-A | Spiropiperidine derivatives | GLAXO GROUP LIMITED (GB) | 1992-05-19 | — | — | US | disclosed |
| EP-0189678-B1 | ELECTROCHEMICAL REDUCTIONS OF PYRIDINE CARBOXAMIDE BASES | REILLY INDUSTRIES, INC. (US) | 1991-11-06 | — | — | EP | disclosed |
| EP-0237908-B1 | PYRIDINE DERIVATIVES | MERCK PATENT GmbH (DE) | 1990-08-29 | — | — | EP | disclosed |
| US-4906642-A | Pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-03-06 | — | — | US | disclosed |
| EP-0330461-A2 | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 1989-08-30 | — | — | EP | disclosed |
| EP-0237908-A2 | Pyridine derivatives | MERCK PATENT GmbH (DE) | 1987-09-23 | — | — | EP | disclosed |
| US-4695352-A | Electrochemical reduction of pyridine carboxamide bases | REILLY TAR & CHEMICAL CORPORATION (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0189678-A1 | Electrochemical reductions of pyridine carboxamide bases | REILLY INDUSTRIES, INC. (US) | 1986-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038490-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | PLAU 1799/4885PRKCI 1962/4885NOTUM 169/4885 |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | PLAU 3284/4885PRKCI 649/4885NOTUM 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.